На главную
Результаты поиска “Adjuvant hormonal therapy in prostate cancer”
Hormone Therapy For Prostate Cancer Treatment- Hormone Therapy Side Effects
Now we have a number of medications available as pills, injections, and implants that can give men the hormonal therapy is also sometimes given after radiotherapy (adjuvant therapy), where aim to reduce chance cancer coming back. Because of their possible side effects (including blood clots and breast enlargement), estrogens have been replaced by other types hormone therapy are you consider as a treatment for prostate cancer? Here is information about the that may experience this get better within 3 to 12 months after ends. And difficulty getting or keeping an erection. His presentation was certainly the most controversial and provocative of session. Zero the end of prostate cancer. How does hormone therapy treat prostate cancer? 4. Make sure you discuss these with your doctor or nurse before start treatment. Your doctor prostate cancer depends on the hormone testosterone in order to grow. Advantages and disadvantages of hormone therapymonitoring the effects therapymanaging side therapycomplementary alternative therapies 15 aug 2017 to minimize therapy medications, your doctor may recommend you take them only until prostate cancer responds treatment. The side effects of hormone therapy and the time it takes to get over some them depend on many factors. Hormone therapy for localised prostate cancer further detailed understanding hormone. Hormonal therapies for advanced prostate cancer information and hormone therapy harvard knowledge canada. You can also talk to our specialist nurses about side effects. Estrogens (female hormones) were once the main alternative to orchiectomy for men with advanced prostate cancer. What does hormone therapy involve? 6. Hormonal therapy can cause a range of side effects that include erection difficulties (ed), lowered sex drive, hot flushes, weight gain, breast swelling and fatigue once reserved solely as treatment for metastatic prostate cancer, hormone is now also used in variety other ways. What are the side effects of hormone therapy for prostate cancer? Loss interest in sex (lowered libido) erectile dysfunctionloss bone densityloss muscle mass and physical strengthinsulin resistance 11 mar 2016 other androgen suppressing drugs. Your doctor or clinical nurse specialist will be able to offer you advice. Typically, you can of the treatment. Hormone therapy what are the side effects? Prostate cancer effects of hormone in men how affects you. He stated that testosterone might not adding radiation therapy to hormone increases survival among men with locally advanced prostate cancer. It depends on the drug you are having and how long have been taking it. For some men, erection problems are permanent. Anti androgens can cause less sexual side effects as agonists but are not effective an orchiestomy or lhrh in treating the disease, leaving it a poor hormonal therapy is main treatment for advanced prostate cancer. We describe here the most common side effects of hormone therapy and how to manage or reduce them. Effective
Просмотров: 464 health tips
Urowebinar: Hormone therapy in prostate cancer  who, how and when
Presenter: Dr. Vijay Ramani Androgens promote the growth of both normal and cancerous prostate cells by binding to and activating the androgen receptor. Once activated, the androgen receptor stimulates the expression of specific genes that cause prostate cells to grow. Hormone therapy, also called androgen deprivation therapy, can block the production and use of androgens inhibiting the cell growth. Different types of androgen deprivation therapy are available in different modalities: neoadjuvant and adjuvant setting, or as a single agent therapy. How to choose the best treatment’s agent, modality and timing will be clarified in this comprehensive webinar.
Просмотров: 1274 European School of Urology
Hormonal therapy in breast cancer
This video describes therapy with anti-estrogens medications in breast cancer.
Просмотров: 25097 charlottecancer
Hormone deprivation  for prostate cancer is dangerous. Avoid it!
Hormone deprivation for prostate cancer is dangerous. Avoid it There is a common misunderstanding on the role of hormones in cancer. Here are some simple rules. 1. Tumor inherits its hormone dependence from the organ where it was formed. Like breast tumor responds to breast hormones like estrogen. 2. Hormones are not carcinogens and do not initiate cancer. They merely accelerate tumor growth, which is known as tumor promotion 2a.Carcinogens initiate a tumor by transforming a normal cell into a malignant. Hormones do not transform cells. They merely promote the growth of transformed cells. 2b. Hormone depletion does not cure cancer. It retards tumor growth and may induce tumor dormancy. 3. As cancer progresses, tumor dependency on hormones declines 3a. This tumor property is known as de-differentiation, which makes tumor independent from hormones. Anti-hormones do not cure cancer, but they may induce tumor dormancy. Unfortunately oncology ignores these rules. Many healthy men carry dormant tumors in their prostates Current treatments, like androgen deprivation, radiation and surgery do not cure cancer. They cannot prevent cancer recurrence and their harm outweighs their benefit. When tumor is confined to the prostate brachytherapy is the treatment of choice. decades. Every second male older than 60 years carries in his prostate a dormant tumor. How did he do it and what is his secret? This capability exists in every male even if he got clinical cancer. It is our duty to harness it during therapy. .
Просмотров: 5730 Gershom Zajicek M.D,
How Is Hormone Therapy Used To Treat Prostate Cancer?
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Hormone therapy may be used in several ways to treat prostate cancer, including: Adjuvant hormone therapy. Hormone therapy that is given after other primary treatments to lower the risk that prostate cancer will come back is called adjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence may receive adjuvant hormone therapy after radiation therapy or prostatectomy (surgery to remove all or part of the prostate gland) (5). Factors that are used to determine the risk of prostate cancer recurrence include the tumor's grade (as measured by the Gleason score), the extent to which the tumor has spread into surrounding tissue, and whether or not tumor cells are found in nearby lymph nodes. Men who have adjuvant hormone therapy after prostatectomy live longer without having a recurrence than men who have prostatectomy alone, but they do not live longer overall (5). Men who have adjuvant hormone therapy after external beam radiation therapy for prostate cancer live longer, both overall and without having a recurrence, than men who are treated with radiation therapy alone (5, 6). Neoadjuvant hormone therapy. Hormone therapy given before other treatments is called neoadjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence often receive hormone therapy before or during radiation therapy, in addition to receiving hormone therapy after radiation therapy. Men who receive hormone therapy in combination with radiation therapy live longer overall than men who receive radiation therapy alone (7). The use of neoadjuvant hormone therapy (alone or in combination with chemotherapy) before prostatectomy has not been shown to prolong survival and is not a standard treatment. Hormone therapy alone. Hormone therapy is sometimes used alone for palliation or prevention of local symptoms in men with localized prostate cancer who are not candidates for surgery or radiation therapy (8). Such men include those with a limited life expectancy, those with advanced local tumor stage, and/or those with other serious health conditions. Hormone therapy used alone is also the standard treatment for men who have a prostate cancer recurrence documented by CT, MRI, or bone scan after treatment with radiation therapy or prostatectomy. Hormone therapy is often recommended for men who have a "biochemical" recurrence—a rapid rise in prostate-specific antigen (PSA) level—especially if the PSA level doubles in fewer than 12 months. However, a rapid rise in PSA level does not necessarily mean that the prostate cancer itself has recurred. The use of hormone therapy in the case of a biochemical recurrence is somewhat controversial. Finally, hormone therapy used alone is also the standard treatment for men who are found to have metastatic disease (i.e., disease that has spread to other parts of the body) when their prostate cancer is first diagnosed (9). Whether hormone therapy prolongs the survival of men who have been newly diagnosed with advanced disease but do not yet have symptoms is not clear (10, 11). Moreover, because hormone therapy can have substantial side effects (see Question 6), some men prefer not to take hormone therapy before symptoms develop. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Просмотров: 303 Martina Santiago
Hormonal Therapy and Prostate Cancer
Dr. Matthew Cooney discusses how hormone therapy is used for prostate cancer and how to minimize treatment side effects. http://prostatecancerletter.com/
Просмотров: 156 Matthew Cooney
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Просмотров: 298 OncLiveTV
Dr. Castle on Adjuvant Versus Early Salvage Therapy in Prostate Cancer
Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.
Просмотров: 57 OncLiveTV
Adjuvant or Salvage RT Post Radical Prostatectomy
Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature comparing the advantages and disadvantages of adjuvant and salvage radiation therapy (RT) for biochemical recurrence. Furthermore, he summarizes consensus guidelines, meta level considerations and debates regarding adjuvant and salvage RT, and prospective trials.
Просмотров: 201 Grand Rounds in Urology
2/2/18: Androgen Deprivation Therapy in Prostate Cancer: Adverse Effects and Strategies to Mitigate
Christos Kyriakopoulos, MD, gives an update on the use of androgen deprivation therapy for the treatment of prostate cancer. Dr. Kyriakopoulos conducts clinical studies of prostate cancer therapies, and received the 2016 Mark and Debbie Attanasio Prostate Cancer Foundation Young Investigator Award. He is an Assistant Professor (CHS) in the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin-Madison The title of his February 2, 2018 Grand Rounds talk is "Androgen Deprivation Therapy in Prostate Cancer: Adverse Effects and Strategies to Mitigate Them." University of Wisconsin Department of Medicine Grand Rounds are presented throughout the academic year and are intended for health care professionals and medical researchers. Unless otherwise indicated, Grand Rounds occurs in the William S. Middleton Memorial Veterans Hospital auditorium, Room A1028, Madison, Wisconsin. All faculty and staff are invited and encouraged to attend. For more information on the Grand Rounds lecture series, visit http://www.medicine.wisc.edu/dom/medicine-grand-rounds
Просмотров: 117 UW Department of Medicine
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?
Dr Mohammad Parvez Shaikh, (Loyola University Medical Centre, Maywood, USA) talks to ecancertv at ASCO GU 2015 about cancer management after radical prostatectomy. He discusses his meta-analysis on the difference between early adjuvant radiotherapy versus watchful waiting management strategies.
Просмотров: 1839 ecancer
Radiation therapy for prostate cancer: What to expect
http://www.sunnybrook.ca // Prostate cancer is the most common malignancy diagnosed in men in North America. Learn about radiation therapy and what to expect.
Просмотров: 167694 Sunnybrook Hospital
Intermittent Hormone Therapy for Rising PSA:  Is it a Good Option?
When the PSA begins to rise after surgery or radiation, many men are told to begin hormone therapy. Some studies suggested that the hormones could be used intermittently rather than continuously. Now a well done study provides important new information for men faced with this problem as discussed in the video.
Просмотров: 977 Gerald Chodak MD
Optimizing Androgen Deprivation Therapy in High-Risk Prostate Cancer
In this segment, panelists discuss the optimization of treatments administered for patients with high-risk prostate cancer following progression on definitive therapies, such as radical prostatectomy. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Просмотров: 635 OncLiveTV
Chemotherapy and Hormonal Therapy in Breast Cancer
Dr. thornton gives an overview of the treatment of breast cancer with hormonal agents and chemotherapy.
Просмотров: 49 Ask the Gynecologist
Say No to Aromatase Inhibitors update
Say No to Aromatase Inhibitors update Androgen and Estrogen deprivation therapy are toxic .There is mounting evidence that hormone deprivation therapy for breast cancer carries significant health risks. Medical therapy does not cure. It induces dormancy. Only the organism maintains tumor dormancy. In women who have had breast cancer, drug treatments are often stopped five years after removal of the primary tumour. A meta-analysis shows that these individuals are still at risk of relapse. The main aim of adjuvant therapy, which is given after cancer treatment, is to reduce the risk of local and distant metastatic disease. Yet this procedure does not cure cancer it only initiates a prolonged tumor dormancy. The risk of distant metastasis rises. One Law for all Cancers: Dysplastic fields have the same topology determined by distinct gene sets called Dysplasia gene sets Hazard rate of recurrence The probability of recurrence for a woman living at a given time. Declining hazard rate indicates that with time tumor remains longer dormant. Estrogen deprivation does not maintain dormancy . Host resistance is an inborn capability to inducetumor dormancy. Medical therapy does not cure. It induces dormancy.Only the organism maintains dormancy
Просмотров: 332 Gershom Zajicek M.D,
What is Neoadjuvant Therapy?
Breast cancer specialist Hal Burstein, MD, PhD from the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, explains what neoadjuvant therapy is, and how and when it's used in treating breast cancer. Learn more about Dana-Farber’s breast oncology program at: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx
Просмотров: 443 Dana-Farber Cancer Institute
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials, called SOFT and TEXT were combined and long-term follow up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries. "This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."
Просмотров: 382 curetoday
Treatment for locally advanced prostate cancer
In this cancer information video, Urologist Shiv Bhanot explains the treatment options for locally advanced prostate cancer. He talks about radiotherapy, hormonal treatment, surgery and watchful waiting. It also features Patrick, who talks about coping through treatment for prostate cancer. Subscribe: http://bit.ly/UsAbto Twitter: https://twitter.com/macmillancancer Facebook: https://www.facebook.com/macmillancancer
Просмотров: 1422 Macmillan Cancer Support
PSMA PET/CT Visualizes Prostate Cancer Recurrence Early, Impacts Radiation Therapy
Jeremie Calais, MD, and Nicholas G. Nickols, MD, PhD, at UCLA explain the potential benefits of PSMA PET/CT for prostate cancer patients with biochemical recurrence after radical prostatectomy. They point out that visualizing sites of prostate cancer recurrence accurately and early enough to guide therapy enables truly precision radiation therapy. The accompanying article is published in the February 2018 issue of The Journal of Nuclear Medicine.
Просмотров: 3711 SNMChannel1
Docetaxil in hormone therapy improves survival in metastatic, hormone-sensitive prostate cancer
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Prof Sweeney (Dana-Farber Cancer Institute, Boston, USA) presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.
Просмотров: 350 ecancer
Breast Cancer - Hormonal Therapy
Просмотров: 100 TeachGlobal
The Benefits of Endocrine Therapy for Treating Prostate Cancer
Learn about the benefits of Endocrine Therapy to treat prostate cancer at Signature Healthcare's Greene Cancer Center.
Просмотров: 5 Signature Healthcare
PSA Elevation After Treatment For Prostate Cancer
Men treated for prostate cancer with radiation or surgery need to have a regular PSA examination. If the PSA rises after treatment, it may indicate recurrence of the cancer. This video describes the evaluation for men who have an elevated PSA after treatment and what are the next options if there is a recurrence of prostate cancer.
Просмотров: 10760 Neil Baum
Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer
Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses a results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.
Просмотров: 265 OncLiveTV
Surgery Versus Radiation in Prostate Cancer
Richard G. Stock, a radiation oncologist with Mount Sinai Hospital, says prostate cancer surgery isn't your typical type of cancer resection. Because the prostate's location and proximity to blood vessels and nerves, it's very difficult for surgeons to remove the prostate tumor and get a clean margin around the tissue, he says. "There are some limitations from a cancer standpoint," he says. "And many patients who have surgery may have microscopic disease left behind and may require adjuvant treatment such as hormone therapy or external beam radiation therapy afterward." Surgery has its side effects, he says, including possible incontinence and sexual dysfunction. Radiation is less invasive, however, it has its own side effects.
Просмотров: 1743 curetoday
Docetaxel + hormone & radiation therapy, for high-risk prostate cancer.
Chicago ASCO Annual Meeting 2015: Press Briefing Progress Against Rare and Common Cancers: Saturday, May 30 - Howard M. Sandler, Chen Hu, Seth A. Rosenthal, et al. A phase III study of adjuvant docetaxel chemotherapy, added to standard hormone and radiation therapy, for men with localized, high-risk prostate cancer. More info: http://oncoletter.ch
Просмотров: 386 oncoletter
Post Prostatectomy Radiation
Dr. Patrick W. McLaughlin presented "Post Prostatectomy Radiation" at the 22nd Annual Scottsdale Prostate Cancer Symposium on Saturday, March 18, 2017.
Просмотров: 1411 Grand Rounds in Urology
Prostate Cancer: Reoccurence After Radical Prostectectomy
When is adjunct therapy (radiation, hormones, combination of both) indicated after a radical prostatectomy? What are the statistics of reoccurrence after a radical prostatectomy? Dr. Eliya answers these questions and more in this March Prostate Cancer Survivorship Series clip.
Просмотров: 4277 MIU Men's Health Foundation
First effective adjuvant chemotherapy for high-risk, localised prostate cancer
Visit http://www.ecancer.org for more Prof Sandler (Cedars Sinai Medical Center, Los Angeles, USA) presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
Просмотров: 82 ecancer
Sequencing of Adjuvant Therapies
Daniel P. Petrylak, MD, provides his perspective on optimal drug sequencing for castration resistant prostate cancer (CRPC) and metastatic CRPC (mCRPC). He reviews the literature regarding available and emerging immunotherapeutic, hormonal, cytotoxic, and DNA damaging treatment options and when to time each drug.
Просмотров: 56 Grand Rounds in Urology
PSA Rise after Treatment-Benign Rise
Bob was nervous when his PSA rose years after his seed implant. Dr. Moran encouraged him not to be alarmed and monitor his PSA before a biopsy or hormone therapy since it may be caused by a benign rise.
Просмотров: 122 Chicago Prostate Cancer Center
Radiation Therapy Side Effects for Prostate Cancer Patients
Michael Steinberg, M.D. - UCLA educates patients on the side effects of radiation therapy.
Просмотров: 73668 Prostate Cancer Research Institute
ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review
Dr Vale talks to ecancertv at ECC 2015 about the results of a systematic review and meta-analysis that examined the role of combining docetaxel or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer. She notes that slightly different conclusions were drawn for metastatic and non-metastatic disease. Adding docetaxel to ADT not only improved patients overall survival (OS) but also reduced the failure rate in metastatic disease. In the non-metastatic setting, failure-free survival was again improved with the chemotherapy but no clear OS benefit was seen. Bisphosphonates had a moderate benefit in the metastatic setting but there was no evidence of any benefit in non-metastatic disease. ecancer's filming at ECC 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Просмотров: 77 ecancer
New Treatment Shown To Slow The Advances Of Prostate Cancer
New Treatment Shown To Slow The Advances Of Prostate Cancer Doctors have developed a successful new treatment for prostate cancer that slows down the condition and helps patients avoid relapse and live longer. The fantastic new result was possible by adding a drug called abiraterone acetate (zytiga) to a standard hormone therapy. The result is based on a clinical trial of almost 2,000 people. It shows that adding abiraterone lowered the relative risk of death by 37 percent and the 3-year survival rate to 83 percent from 76 percent based on the standard therapy alone. The study was presented at the 2017 American Society of Clinical Oncology Annual meeting by lead author Professor Nicholas James from the Queen Elizabeth Hospital in Birmingham, UK. “Abiraterone not only prolonged life, but also lowered the chance of relapse by 70% and reduced the chance of serious bone complications by 50%,” Professor James said in a statement. “We believe that the upfront care for patients newly diagnosed with advanced prostate cancer should change.” The combined therapies fight the production of testosterone around the body. Testosterone stimulates the growth of prostate cancer cells so the standard treatment, known as androgen deprivation therapy (ADT), acts on the testicles and stops the production of hormones. Unfortunately, other organs, including the prostate glands, continue to produce small quantities of testosterone and this is where abiraterone comes in. The substance target the enzyme that produces testosterone and similar hormones everywhere. The patients were followed up on average 40 months after the two types of treatment started. According to the study, over that time 262 deaths occurred in the group using standard therapy and 184 in the group using abiraterone. Of these deaths, two in the abiraterone group and one in the standard were due to the treatment. While the therapy is promising in term of survival rate, abiraterone had more severe side effects than the standard approach. Forty-one percent of patients complained of severe side effects when taking abiraterone, compared to 29 percent from the standard group. Side effects included cardiovascular and liver problems. Previous studies showed successful results in fighting a particularly aggressive form of prostate cancers by using a mixture of hormonal therapy and a chemotherapy drug known as docetaxel. There is a chance that some patients might benefit by including abiraterone into the mix but more studies are necessary to confirm that. The team is currently planning molecular analysis of tissue samples from patients that could benefit from the new cocktail but, for now, it’s too early to tell.
Просмотров: 63 General Health Tips
Chemohormonal therapy for hormone-sensitive newly metastatic prostate cancer
Ten years after pivotal results of docetaxel in castration-resistant prostate cancer, J.Bellmunt discusses results of chemohormonal therapy in patients with hormone-sensitive, newly diagnosed metastatic prostate cancer, noting how rare such magnitude of effect is seen in oncology. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Просмотров: 910 European Society for Medical Oncology
Prostate Cancer: PSA After Surgery
How necessary is the PSA blood test after treatment of prostate cancer? Why do some PSA levels fluctuate after surgery? Listen to Dr. Hafron explain in this clip from our April Prostate Cancer Survivorship Series.
Просмотров: 5906 MIU Men's Health Foundation
Dr. Patel on Early Treatment With Docetaxel for Metastatic Prostate Cancer
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 308 Targeted Oncology
Testosterone and Prostate Cancer: Is There a Link?
Dr. Abraham Morgentaler presented "Testosterone and Prostate Cancer: Is There a Link?" at the 22nd Annual Scottsdale Prostate Cancer Symposium on Friday, March 17, 2017.
Просмотров: 1365 Grand Rounds in Urology
PSA Levels After Prostate Cancer Treatment
Dr. Tutrone explains how different types of treatment require different PSA levels to be considered cured, as well as how long PSA levels have to be monitored for recurrence of prostate cancer. LAST WEEK'S VIDEO - Prostatectomy Recovery Explained http://youtu.be/hDc5sBUxejY SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING PROSTATE CANCER NEWS http://www.youtube.com/subscription_center?add_user=ProstateCancerLive VISIT PROSTATECANCERLIVE.com FOR TONS OF INFORMATIVE VIDEOS http://www.prostatecancerlive.com/# SUGGEST THE NEXT TOPIC FOR OUR PROSTATE CANCER EXPERTS! http://www.prostatecancerlive.com/# CONNECT WITH US! Google+: http://bit.ly/17F4WQr Facebook: https://www.facebook.com/pages/Prostate-Cancer-Live/107234326132305 Twitter: https://twitter.com/ProstateLive ______ Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Просмотров: 18389 Prostate Cancer Live
Dr. Sweeney on Chemotherapy in Prostate Cancer
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.
Просмотров: 125 OncLiveTV
When Should I Stop Anti-Hormone Therapy?
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ When should you stop taking Anti-Hormone Therapy treatment for you breast cancer? Find out from Dr. Jay Harness in the video above. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 387 Breast Cancer Answers®
How Do Hormones Treat Cancer?
Hormone therapies for breast cancer treatment hormonal therapy treating hormone health encyclopedia and webmd. Hormone therapy cancer research uk. Analogs of gonadotropin releasing hormone (gnrh) can be used to induce a chemical castration, that is. At cancer treatment centers of america (ctca), we may hormonal therapies do have side this is also associated with how can hormones affect the growth breast cancer? Hormones like therapy be called anti hormone. Hormone therapy on its own won't cure your prostate hormonal in oncology is hormone for cancer and one of the major modalities it was formerly used breast treatment, but has since been replaced by more selective aromatase inhibitors. Having the right information will help you make decision for if testosterone is taken away, cancer usually shrink, even it has spread to other parts of your body. Hormonal therapy hematology & medical oncology cancer hormone national breast foundationoncolink. Hormone therapy can learn how hormone therapies slow or stop the growth of for breast cancer treatment is different than menopausal 14 feb 2017 hormonal medicines treat receptor positive cancers hrt contains estrogen and contain progesterone other in cases, hormones kill cells, make cells grow more slowly, them from growing. Hormone therapy as a cancer treatment may 10 apr 2015 tamoxifen and breast prevention; Can other drugs prevent common hormone for include but even in cases where removing or killing the isn't possible, can help slow down growth. Think of it as the 4 apr 2016 meanwhile, research is ongoing to study potential efficacy hormonal manipulation in treating other cancer types. Hormone therapy what are the side effects? Prostate cancer breast treatment hormone is hormonal for cancer? Hormonal early stage receptor. Hormone therapy cancer treatment centers of america. Hormone therapy for cancer national institute. Hormonal therapies treating breast cancer macmillan hormone therapy hormonal (oncology) wikipedia. Hormone therapy for breast cancer american society. Hormone treatment fights prostate cancer webmd. Hormone therapy cancer research ukcancer uk. Though it isn't a cure, hormone are you consider therapy as treatment for prostate cancer? Exercise is probably the best thing man can do to prevent many of these side effects oestrogen play part in stimulating some breast cancers grow, there number different therapies that work 20 jul 2016 hormonal medicines whole body receptor positive cancerslowering amount estrogen or blocking its also reduce risk an early stage, 16 feb adjuvant given after surgery, chemotherapy, and therapy, likely effects, how long will last, your doctors may tell options. Cancers that can be hormone sensitive include 18 aug 2016 therapy also used to treat cancer has come back after about 2 out of 3 breast cancers are receptor positive 29 apr 2015 is prostate and use the side effects you have will depend on type prevent cells from getting hormones they need grow. Hormone therapy changes hormone levels in the body and can stop or slow down doctors use it to treat some cancers such as breast prostate cancer is a treatment that uses medicines block lower does not work for all.
Просмотров: 52 Pan Pan 3
ESTRO 2010: Radiation treatment of prostate cancer
Dr Jereczek-Fossa speaks about the use of radiotherapy to treat prostate cancer, the importance of image guidance and the role it plays in adjuvant post operative treatment. Dr Jereczek-Fossa also explains the choice patients face whether to have robotic surgery or image guided radiotherapy, considers the option of adjuvant surgery after radiotherapy and discusses the benefits of anti-androgen hormone therapy that have been revealed in recent clinical trials. Dr Barbara Jereczek-Fossa of the European Institute of Oncology in Milan, Italy, speaking to ecancer.tv at the European Society for Therapeutic Radiology and Oncology meeting (ESTRO 29), in Barcelona.
Просмотров: 773 ecancer
Understanding hormone therapy for breast cancer video
Why does hormone therapy work for some breast cancers but not others? Breast cancer expert Robert Carlson, MD, of the Stanford Comprehensive Cancer Center, explains the role of estrogen and progesterone some breast cancers in this video from the National Comprehensive Cancer Network (NCCN). NCCN, a not-for-profit alliance of 21 leading cancer centers—including Stanford—is dedicated to improving the quality and effectiveness of care for cancer patients. For more information on breast cancer and other cancers, including the NCCN Guidelines for Patients, visit www.NCCN.com.
Treating High-Risk Localized Prostate Cancer
Multiple treatment options exist for patients with high-risk localized or advanced prostate cancer, making the optimal treatment decision difficult, since it will likely require multiple modalities. In this segment, panelists explore the intricacies of treating patients in this setting. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Просмотров: 3256 OncLiveTV
Prostate Cancer: Management of Rising PSA after Combination of Prostatectomy and External Radiation
Some men have a rising PSA despite both radical prostatectomy and external radiation. This video reviews the current information available on how to manage this problem.
Просмотров: 8377 Gerald Chodak MD
When is radiation therapy appropriate after surgery for prostate cancer? (Colleen Lawton, MD)
Colleen Lawton, MD, radiation oncologist, talks about which patients need radiation therapy after prostate cancer surgery. Dr. Lawton is part of the Froedtert & the Medical College of Wisconsin Prostate and Urologic Cancer Program in Milwaukee, Wis. http://www.froedtert.com/prostate-cancer